iTeos Therapeutics, Inc. (ITOS)

10.95 -0.26 (-2.32%) At close: 04:00PM EDT

iTeos Therapeutics, Inc.

321 Arsenal Street
Suite 301 Building 312
Watertown, MA 02472
United States
339 217 0161
https://www.iteostherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 125

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Michel Detheux Ph.D.	Pres, CEO & Director	922.38k	N/A	1966
Mr. Matthew A. Call M.B.A.	Chief Operating Officer	638.55k	N/A	1973
Mr. Matthew Gall	Chief Financial Officer	N/A	N/A	1977
Dr. Yvonne McGrath Ph.D.	Chief Scientific Officer	N/A	N/A	1974
Mr. Ryan Baker	Head of Investor Relations	N/A	N/A	N/A
Ms. Adi Osovsky	VP & Head of Legal	N/A	N/A	N/A
Mr. Phillipe Brantegem	Vice-Pres of HR	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Corporate Governance

iTeos Therapeutics, Inc.’s ISS Governance QualityScore as of September 28, 2023 is 9. The pillar scores are Audit: 8; Board: 7; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.